Management of Decompensated Cirrhosis

Primary Strategy: Treat the Underlying Cause

The American Association for the Study of Liver Diseases recommends etiological treatment must be initiated immediately as this is associated with decreased risk of further decompensation and increased survival in patients with decompensated cirrhosis 1

The European Association for the Study of the Liver suggests spironolactone with or without furosemide as first-line treatment for ascites, initiated at low doses and titrated carefully, with the goal of achieving a daily weight loss of 0.5 kg in patients with edema and 1 kg in those without edema 2
The American College of Gastroenterology recommends fluid restriction is unnecessary unless serum sodium drops below 120-125 mmol/L in patients with cirrhosis and ascites 2

The American Association for the Study of Liver Diseases recommends lactulose as first-line therapy for hepatic encephalopathy, reducing mortality and recurrent overt hepatic encephalopathy in patients with cirrhosis 2

The Infectious Diseases Society of America suggests norfloxacin 400 mg orally twice daily for infection prophylaxis in patients with decompensated cirrhosis, reducing the risk of spontaneous bacterial peritonitis and hepatorenal syndrome 1
The American College of Gastroenterology recommends ceftriaxone 1 g IV every 24 hours for up to 7 days for variceal bleeding prophylaxis in patients with decompensated cirrhosis or quinolone-resistant settings 2

The American Association for the Study of Liver Diseases suggests statins show promise in reducing portal hypertension and improving survival through pleiotropic effects in patients with cirrhosis, but require validation in future studies before routine recommendation 1

The European Association for the Study of the Liver recommends enoxaparin (12-month course) was safe and effective in preventing portal vein thrombosis and may delay decompensation in patients with cirrhosis, but requires further validation 1

The American College of Gastroenterology recommends avoiding nephrotoxic drugs and NSAIDs as they can precipitate renal failure and convert diuretic-sensitive to refractory ascites in patients with cirrhosis 3
The American Association for the Study of Liver Diseases suggests early referral for liver transplantation evaluation is essential as decompensation significantly worsens prognosis in patients with cirrhosis 2

The American Association for the Study of Liver Diseases recommends spironolactone (100-400 mg/day) with or without furosemide (up to 160 mg/day) as the guideline-recommended pharmacologic approach for ascites management 4
The European Association for the Study of the Liver suggests large-volume paracentesis with albumin replacement (8 g/L of ascites removed) for refractory or tense ascites 4
Dietary sodium restriction to 90 mmol/day (5.2 g salt/day) is recommended for ascites management 4

The American College of Gastroenterology notes that rifaximin 550 mg twice daily is indicated for hepatic encephalopathy prevention in patients with a prior episode, and may have a secondary effect on ascites 5
The International Ascites Club suggests that rifaximin may be considered for refractory ascites without prior hepatic encephalopathy, at a dose of 200 mg four times daily, if ascites is truly refractory to diuretics and repeated paracentesis, and the patient has a high risk for complications 4

The use of rifaximin 600 mg twice daily starting 14 days before TIPS reduces post-TIPS hepatic encephalopathy from 53% to 34%, as recommended by the Journal of Hepatology 5

The American Liver Foundation notes that rifaximin does not replace standard ascites management with diuretics and paracentesis 4
The development of refractory ascites is itself an indication for liver transplant evaluation, regardless of rifaximin use, as recommended by the Gut journal 4